ELSEE PHARMACOGENOMICS - Personalizing Medication Usage for Optimal Treatment
-
Pharmacogenomics testing is a type of genetic testing that can help identify genetic variations that affect how a person's body responds to certain medications. By analyzing a person's DNA, pharmacogenomics testing can provide valuable information that can help doctors personalize medication regimens for optimal treatment.
-
Here are some of the key benefits of pharmacogenomics testing:
-
Personalized medication regimens: Pharmacogenomics testing can help doctors tailor medication regimens to a person's specific genetic makeup. This can lead to more effective treatments with fewer side effects.
-
Improved safety: Pharmacogenomics testing can help identify medications that may be unsafe or ineffective for a person based on their genetic makeup. This can reduce the risk of adverse drug reactions and potentially save lives.
-
Better understanding of medication effectiveness: By analyzing the DNA of patients who respond well to certain medications, pharmacogenomics testing can help researchers better understand the underlying mechanisms of drug effectiveness. This can lead to the development of new treatments and medication regimens.
-
Reduced healthcare costs: By identifying the most effective medication regimen for a person, pharmacogenomics testing can reduce healthcare costs by minimizing the need for ineffective treatments or trial-and-error medication adjustments.
-
Improved patient outcomes: Personalized medication regimens can improve patient outcomes, including faster recovery times, reduced risk of complications, and improved quality of life.
-
-
If you are interested in personalized medication regimens, talk to your doctor about pharmacogenomics testing. It could provide valuable information that can improve your treatment options, reduce your risk of adverse drug reactions, and ultimately, improve your health and wellbeing.
-
In this report, the medications/drugs will be displayed according to drug class with your drug metabolizing status, effect on efficacy and adverse effects/safety concerns if any. Here are some instances of major genes that will be tested in this report:
-
CYP3A5 gene. The CYP3A5 gene is expressed in the liver, intestine and extrahepatic tissue and is one of the cytochrome P450 enzymes that facilitates the metabolism and elimination of drugs. Drugs Metabolized: Immunosuppressants (tacrolimus, sirolimus), HIV antiviral (atazanavir), Sedatives (midazolam).
-
SLCO1B1 gene. The SLCO1B1 gene encodes a protein that mediates the active transport of various anionic compounds, such as the statin drugs, into the liver cells. Drugs Metabolized: Statins (simvastatin, rosuvastatin, pravastatin, and other statin drugs).
-
DPYD gene. The DPYD gene expressed in many cell types throughout the body, with liver and peripheral blood being the major sites. The DPYD enzyme is involved in the metabolism of fluoropyrimidine chemotherapeutic drugs. Drugs Metabolized: Chemotherapy (5-fluorouracil, capecitabine).
-
VKORC1 gene. The VKORC1 gene encodes the VKORC1 (Vitamin K epoxide reductase) protein, which is a key enzyme in the Vitamin K cycle. Vitamin K is an important cofactor for several coagulation factor proteins needed for clotting. Warfarin s a commonly prescribed oral anticoagulant used to prevent thromboembolic diseases by acting as an inhibitor of VKORC1 enzyme activity, leading to a reduced amount Vitamin K cofactor. Depending on the genotype, an individual may be more sensitive or more resistant to warfarin therapy. Drugs Metabolized: Blood thinners (warfarin).
-
OPRM1 gene. The OPRM1 gene provides instructions for making a protein called the mu (μ) opioid receptor, which is part of the body’s internal system for regulating pain, reward, and addictive behaviors. When opioids attach (bind) to the receptors, the interaction triggers a series of chemical changes within and between neurons that lead to feelings of pleasure and pain relief. Drugs Metabolized: Opioids (Fentanyl, Afentanyl, Tramadol, Morphine).
-
CYP2C19 gene. The CYP2C19 gene is predominately expressed in the liver and encodes an enzyme that contributes to the metabolism of a large number of clinically relevant drugs and drug classes. Drugs Metabolized: Blood thinners (clopidogrel), Muscle relaxants (carisoprodol), Antidepressants and analgesics (amitriptyline), SSRI antidepressants (sertraline), Antifungals (voriconazole).
-